Table 1.
Chronologic overview of the included studies
| Ref. | Study | Total n | RAI + |
Reported outcomes | Data source | Patient cohort |
|---|---|---|---|---|---|---|
| [7] | Kwon 2017 | 1932 | 85% | RFS | Seoul registry (1998–2009) | 100% microcarcinoma |
| [8] | Yang 2017 | 11,832 | 65–93% |
OS (5 years, 10 years) |
NCDB database (2002–2012) | 100% stage IV |
| [9] | Zhang 2017 | 8601 | 68% |
OS; CSS (5 years, 10 years) |
SEER database (2004–2013) | 100% intermed. risk |
| [10] | Al-Qahtani 2015 | 326 | 56% |
DFS (5 years, 10 years) |
Riyadh registry (2000–2012) | 100% microcarcinoma |
| [11] | Carhill 2015 | 4941 | 74% | OS; DFS | NTCTCSG registry (1987–2012) | 43% stage I, 27% II, 24% III (5% IV) |
| [12] | Kiernan 2015 | 32,119 | 24% |
OS (5 years, 10 years) |
NCDB database (1998–2011) |
78% stage I (14% II, 7% III, 1% IV) |
| [13] | Ruel 2015 | 21,870 | 71% | OS | NCDB database (1998–2006) | 100% intermed. risk |
| [14] | Nixon 2013 | 1129 | 61% |
CSS; RFS (5 years) |
MSKCC registry (1986–2005) | 41% low risk, 45% intermed. (14% high) |
| [15] | Kim 2013 | 704 | 82% | RFS | Korean registry (1994–2004) | 100% microcarcinoma |
| [16] | Schvartz 2012 | 1298 | 70% | OS; DFS (10y) | French registry (1975–2004) | 100% low risk |
| [17] | Lin 2009 | 7818 | 22% | OS; CSS | SEER database (1988–2005) | 100% microcarcinoma |